Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amplia Therapeutics ( (AU:ATX) ) has provided an announcement.
Amplia Therapeutics has successfully raised A$27.5 million through an institutional placement and a share purchase plan to support its ongoing and future clinical trials, including the ACCENT and AMPLICITY trials for its lead drug, narmafotinib. This capital raise, strongly backed by both existing and new investors, positions the company to accelerate towards a potential pivotal phase 2b/3 trial in 2026 and ensures funding into 2027, highlighting investor confidence in Amplia’s strategic direction and potential impact in the oncology sector.
More about Amplia Therapeutics
Amplia Therapeutics Limited is a biotechnology company based in Melbourne, Australia, focusing on the development of targeted therapies for cancer treatment. Its primary product is narmafotinib (AMP945), which is being tested in trials for pancreatic and ovarian cancers.
Average Trading Volume: 6,618,883
Technical Sentiment Signal: Buy
Current Market Cap: A$110.8M
Learn more about ATX stock on TipRanks’ Stock Analysis page.